Artificial Intelligence Self Harm Application

Launched by PAKISTAN INSTITUTE OF LIVING AND LEARNING · Aug 25, 2023

Keywords

ClinConnect Summary

This clinical trial, called the Artificial Intelligence Self Harm Application (AISHA), is studying a new tool designed to help young people who may be at risk of self-harm or suicide. The trial aims to see how well this app works alongside regular treatment for mental health issues. It will take place in various locations in Pakistan, where researchers will compare the experiences of young people using the app with those who only receive standard treatment.

To participate, individuals must be between 16 and 25 years old and have recently been treated for self-harm. They should also be comfortable using mobile devices and able to read in either Urdu or English. Participants will be asked to provide their consent and will engage in activities related to the app while receiving their usual care. The study is still in the planning stages and has not yet begun recruiting participants. The researchers will also conduct interviews and focus groups to better understand how to implement this app in mental health services across the country.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All patients presented to the participating family physicians, community health centres, emergency departments or admitted to a general hospital after an episode of self-harm at participating sites.
• • Age 16 to 25 years
• • Participants must be familiar with functioning of handheld mobile devices (mobile phones, tablets).
• • Able to read Urdu or English language.
• • Individuals able to provide written informed consent.
• • Have an android mobile phone/device
• Exclusion Criteria:
• • Participants with ICD-I0 mental disorder; due to a general medical condition or substance misuse, dementia, delirium, alcohol or drug dependence, schizophrenia, bipolar disorder, learning disability which prevents participation.
• • Participants needing inpatient psychiatric treatment as determined by their clinical teams